Showing results (21-30 of 1,241) with videos related to
Sort By:
Pageof 125
Expert Opinion on Drug Metabolism & Toxicology|May 7, 2013
Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerationsThomas MüllerExpert Review of Neurotherapeutics|September 24, 2013
Current status of safinamide for the drug portfolio of Parkinson's disease therapyThomas MüllerExpert Review of Neurotherapeutics|June 7, 2013
Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's diseaseThomas MüllerNeurology International|March 27, 2026
No New Relevant Treatment Options for L-DOPA-Induced Dyskinesia from a Clinician's Point of ViewThomas MüllerExpert Opinion on Investigational Drugs|December 9, 2016
Investigational agents for the management of Huntington's diseaseThomas MüllerTherapeutic Advances in Neurological Disorders|March 4, 2014
Tolcapone addition improves Parkinson's disease associated nonmotor symptomsThomas Müller, Expert Opinion on Pharmacotherapy|July 10, 2020
An evaluation of subcutaneous apomorphine for the treatment of Parkinson's diseaseThomas MüllerJournal of Experimental Pharmacology|April 7, 2021
Experimental Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of the EvidenceThomas MüllerThe Psychoanalytic Quarterly|April 28, 2004
On psychotic transference and countertransferenceThomas MüllerExpert Review of Molecular Diagnostics|April 11, 2022
Perspective: cell death mechanisms and early diagnosis as precondition for disease modification in Parkinson's disease: are we on the right track?Thomas MüllerPageof 125